Genprex Inc (GNPX) USD0.001
- Add to watchlist
- This stock can be held in a
Business summary
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on the development of gene-based therapies for patients with unmet medical needs. The Company's lead oncology drug candidate, REQORSA Immunogen therapy drug (quaratusugene ozeplasmid), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA consists of the TUSC2 gene-expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (its ONCOPREX Nanoparticle Delivery System). The Company is also using a different gene therapy delivery system in developing its pre-clinical diabetes candidates, GPX-002 and GPX-003. Its diabetes gene therapy is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.
Contact details
Important dates
General stock information
- Short code:
- GNPX
- ISIN:
- US3724462037
- Market cap:
- $5.18 million
- Shares in issue:
- 1.91 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.